top of page
Team Members
frontpage background.png

Innovative therapeutics with a de-risk approach 

PurMinds operates out of a NeuroLab and Health Canada Controlled Substance approved production facility in Ontario, Canada.


PurMinds owns and operates a portfolio of technical assets and special licenses that give the Company a competitive edge. We de-risk our enterprise portfolio by innovating best-in-class therapeutics with proven mechanisms of action. In addition, PurMinds is developing our own proprietary botanical psilocybin formulation for global supply, serving as a revenue-generating asset.


Our People

With strong management, scientific and business backgrounds, our team is committed to developing best-in-class disease-modifying therapeutics for neurological conditions. Collectively, we work to develop novel medicines that address underlying pathologies associated with a variety of CNS disorders. Ultimately, our goal is to revolutionize patient outcomes and enhance their quality of life.

Our Team



President & Chief Executive Officer

A serial entrepreneur and strategic visionary with 15+ years of corporate banking experience and 8+ years of strategic management and business development work in investment, biotech and branding marketing field. 


Chief Scientific Officer

Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience. He worked as a Professor for over 40 years at a number of prestigious universities in the field of medicinal chemistry, and is known for his research on 5-HT receptors, HDAC  and GSK-3 inhibitors, and has over 100 patents and over 550 publications. 


Chief Business Officer

A senior executive with 20+ years' experience in strategic leadership, business development, technology transfer, revenue building, process development and manufacturing, including experience in scaling up CDMO operations and reviewing CMC sections of IND and NDA applications.


Chief Innovation Officer

A recognized leader in neuroscience and neuropharmacology; specializing in psychedelic clinical development, neurodegeneration, and  nutritional neurobiology; with 15 years of expertise in translational medicine spanning from molecules to mind 


Chief Financial Officer & 

Chief Operating Officer

Senior Financial Leader with 30+ years experience in FP&A, Business Valuation, general accounting, risk management, and in driving financial and operational excellence.

Dr Jianmin Duan.png

Vice President,

ADMPK & Pharmacology

Experienced team leader with 20+ years of track records in drug absorption, distribution, metabolism, excretion, pharmacokinetics and pharmacology. Dr. Duan is part of the success exit story of Inversago Pharma as their Executive VP, Pharmacology/DMPK.

Jian Chen Hi Res Pic_edited_edited.png

Vice President, NeuroLabs

Over 25 years of experience in laboratory operation and management, scientific research team leadership in chemistry, multi-omics for biomarker based precision medicine. 

Bi Kim.png

Vice President, Technology

Strong science background with extensive experience in research and development for laboratory and production technology. Ms. Kim plays a key role in the advancement of PurMinds botanical production process, and is desired to support the development of new therapies for devastating neurological diseases. 

Travis Francis_edited.jpg

Senior Director,

Scientific Programs

Dr. Francis is a neuroscientist specializing in behavioural neuropharmacology, with 6+ years of experience investigating pathological mechanisms and therapeutic strategies for a variety of psychiatric and neurological conditions.


Clinical Investigator

Co-Principal Investigator of Psychedelic clinical trials and adjunct teaching faculty in Johns Hopkins University.


Director, Quality and

Regulatory Affairs

With extensive experience and a long track-record in quality assurance and regulatory affairs, Mr. Wallace is helping Purminds navigate the regulatory framework of Health Canada, the US FDA and the European Medicines Agency (EMA).

Scientific Advisory Board

Shengtao Ho_edited_edited.png

Sheng-Tao Hou


Professor of Neurobiology 


Brain Research Center

Southern University of Science and Technology (SUSTech)

Adjunct Professor

University of Ottawa Health Services 

Honorary Professor

Queensland Brain Institute

The University of Queensland (UQ)

Executive Director, 

SUSTech-UQ Joint Center for Neuroscience & Neural Engineering


Mathieu Miron


Partner & 

Patent Agent,

registered to act before the Canadian and United States Patent Offices, with specialties in biochemistry, organic chemistry, biotechnology, pharmaceutical inventions, food science, medical devices, simple mechanics and business methods


bottom of page